文献速递骨软组织肉瘤与黑色素瘤

IIB-IIID期黑色素瘤患者基于预测性生物标志物降阶梯辅助治疗的意愿:横断面调查

Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey.
PubMed 文献 · Eur J Cancer · 2026-09-25

该横断面调查纳入159例AJCC第8版IIB-IIID期黑色素瘤患者,评估其基于预测性生物标志物(ctDNA、GEP)降阶梯辅助治疗的意愿。结果显示97.4%认为生物标志物研究重要,但仅38.0%在五年结果良好时愿放弃辅助治疗,73.3%要求检测准确率≥95%。低健康素养与愿意放弃治疗相关(OR 0.61),而学位为学业学位者在调整健康素养后与意愿相关(OR 2.31)。

要点

  • 患者对生物标志物兴趣高,但仅38.0%愿在有利结果下放弃辅助治疗。
  • 73.3%要求检测准确率≥95%,仅18.3%接受10%假阴性率下降阶梯。
  • 低健康素养(OR 0.61)和学业学位(OR 2.31)与放弃治疗意愿相关。

核心结论

  • 黑色素瘤患者对预测性生物标志物兴趣强烈,但要求高准确率且对假阴性耐受性低。
  • 实施生物标志物指导的决策需要针对预测不确定性的患者教育。

研究设计与样本

  • 横断面调查,连续纳入单一三级中心的AJCC第8版IIB-IIID期黑色素瘤患者,N=159,应答率80.7%。
  • 使用自编问卷评估生物标志物相关态度,并采用验证工具评估决策偏好、健康素养、进展恐惧和焦虑。

主要发现

  • 34.2%患者此前对生物标志物有了解,97.4%认为生物标志物研究重要。
  • 82.3%期望个体化治疗为主要获益,91.1%希望获得不良事件预后信息,83.5%希望获得疾病进展信息。
  • 给定有利的五年检测结果,38.0%愿意放弃辅助治疗;73.3%要求检测准确率≥95%。
  • 66.9%认为治疗不足比治疗过度更糟;仅18.3%在假阴性率10%时接受降阶梯治疗。
  • 低健康素养(OR 0.61,p=0.045)和学业学位(OR 2.31,p=0.037)与愿意放弃治疗相关,后者仅在调整健康素养后出现。

临床怎么用

  • 与患者讨论生物标志物指导的降阶梯治疗时,需明确检测准确率和假阴性风险。
  • 针对低健康素养患者加强教育,以支持知情决策。

局限性

  • 单中心横断面设计可能限制普遍性。
  • 自编问卷可能引入测量偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Predictive biomarkers such as circulating tumour DNA (ctDNA) and gene expression profiling (GEP) may guide adjuvant melanoma therapy de-escalation by identifying low-recurrence-risk patients. However, their implementation depends on patient willingness to act on test results. This study investigated patient preferences regarding predictive biomarkers. METHODS: A cross-sectional survey was conducted among consecutive patients with AJCC 8th-edition stages IIB-IIID melanoma at a tertiary centre (N = 159, response rate 80.7%). The self-constructed questionnaire assessed biomarker-related attitudes, including willingness to forgo adjuvant therapy, accuracy thresholds, and undertreatment-overtreatment trade-offs, alongside sociodemographic characteristics. Validated instruments assessed decision-making preferences (Control Preferences Scale), health literacy (HLS-EU-Q16), fear of progression (PA-F-KF), and anxiety (GAD-7). Alongside descriptive analyses, logistic regression examined factors associated with willingness to forgo therapy. RESULTS: Despite limited prior awareness (34.2%), 97.4% considered biomarker research important. Most patients expected personalised therapy (82.3%) as primary benefit and wished to receive prognostic information on adverse events (91.1%) and disease progression (83.5%). Given a favourable five-year test result, 38.0% would forgo adjuvant therapy; 73.3% required ≥ 95% test accuracy. Two-thirds (66.9%) considered undertreatment worse than overtreatment; only 18.3% would accept de-escalation given a 10% false-negative rate. Lower health literacy (OR 0.61, p = 0.045) and an academic degree (OR 2.31, p = 0.037) were associated with willingness to forgo therapy. The latter emerged only after adjustment for health literacy, potentially reflecting a suppression effect. CONCLUSIONS: Melanoma patients demonstrate strong interest in biomarkers but demand high accuracy with low tolerance for false-negative predictions. Implementation of biomarker-guided decisions requires targeted patient education addressing predictive uncertainty.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Blomen CL, Kelpe J, Kött J, et al. Patient willingness to de-escalate adjuvant therapy based on predictive biomarker results in stage IIB-IIID melanoma: A cross-sectional survey. Eur J Cancer. 2026. PMID: 42804856. doi:10.1016/j.ejca.2026.117061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。